other material
confidence high
sentiment positive
materiality 0.75
Perspective Therapeutics reports positive Phase 1/2a data for [212Pb]VMT-α-NET in NETs; pursuing dose escalation
Perspective Therapeutics, Inc.
- No dose-limiting toxicities observed at 2.5 and 5.0 mCi doses; safety profile favorable.
- Eight of nine patients had durable disease control; six of nine had measurable tumor reduction, one confirmed RECIST response.
- Safety Monitoring Committee recommends dose escalation to Cohort 3; company to engage with FDA.
- Plans to file IND for PSV359 (FAP-α targeting) by end of 2024.